Literature DB >> 21848534

Cross-sectional study of antimicrobial-resistant bacteria in horses. Part 1: Prevalence of antimicrobial-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus.

T W Maddox1, P D Clegg, P J Diggle, A L Wedley, S Dawson, G L Pinchbeck, N J Williams.   

Abstract

REASONS FOR PERFORMING STUDY: The increasing prevalence of antimicrobial-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and antimicrobial-resistant Escherichia coli represents a significant problem. However, the carriage of such bacteria by horses in the UK has not been well characterised.
OBJECTIVES: To estimate the prevalence of nasal carriage of MRSA and faecal carriage of antimicrobial-resistant E. coli amongst horses in the general equine community of the mainland UK.
METHODS: A cross-sectional study of horses recruited by 65 randomly selected equine veterinary practices was conducted, with nasal swabs and faecal samples collected. Faecal samples were cultured for antimicrobial-resistant E. coli. Nasal swabs were cultured for staphylococcal species; methicillin-resistant isolates identified as S. aureus were characterised by SCCmec and spa gene typing. Multilevel logistic regression models were used to calculate prevalence estimates with adjustment for clustering at practice and premises levels. Spatial variation in risk of antimicrobial resistance was also examined.
RESULTS: In total, 650 faecal samples and 678 nasal swabs were collected from 692 horses located on 525 premises. The prevalence of faecal carriage of E. coli with resistance to any antimicrobial was 69.5% (95% CI 65.9-73.1%) and the prevalence of extended-spectrum β-lactamase (ESBL)-producing E. coli was 6.3% (95% CI 4.1-9.6%). The prevalence of nasal carriage of MRSA was 0.6% (95% CI 0.2-1.5%). Spatial analysis indicated variation across the UK for risk of carriage of resistant and multidrug-resistant (resistant to more than 3 antimicrobial classes) E. coli. CONCLUSIONS AND POTENTIAL RELEVANCE: Carriage of MRSA by horses in the community appears rare, but the prevalence of antimicrobial-resistant E. coli (including ESBL-producing E. coli) is higher. A high prevalence of antimicrobial-resistant bacteria could have significant health implications for the horse population of the UK.
© 2011 EVJ Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848534     DOI: 10.1111/j.2042-3306.2011.00441.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  17 in total

1.  Antimicrobial resistance in bacteria isolated from horses from the Atlantic Provinces, Canada (1994 to 2013).

Authors:  Babafela B Awosile; Luke C Heider; Matthew E Saab; J T McClure
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

2.  Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology-Veterinary Extension.

Authors:  A M O'Connor; J M Sargeant; I R Dohoo; H N Erb; M Cevallos; M Egger; A K Ersbøll; S W Martin; L R Nielsen; D L Pearl; D U Pfeiffer; J Sanchez; M E Torrence; H Vigre; C Waldner; M P Ward
Journal:  J Vet Intern Med       Date:  2016-11-07       Impact factor: 3.333

3.  Fecal Carriage of Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli in Horses.

Authors:  Joost Hordijk; Evangelia Farmakioti; Lidwien A M Smit; Birgitta Duim; Haitske Graveland; Mathijs J P Theelen; Jaap A Wagenaar
Journal:  Appl Environ Microbiol       Date:  2020-04-01       Impact factor: 4.792

4.  Horses in Denmark Are a Reservoir of Diverse Clones of Methicillin-Resistant and -Susceptible Staphylococcus aureus.

Authors:  Md Zohorul Islam; Carmen Espinosa-Gongora; Peter Damborg; Raphael N Sieber; Rikke Munk; Louise Husted; Arshnee Moodley; Robert Skov; Jesper Larsen; Luca Guardabassi
Journal:  Front Microbiol       Date:  2017-04-03       Impact factor: 5.640

5.  Antimicrobial resistance and the presence of extended-spectrum beta-lactamase genes in Escherichia coli isolated from the environment of horse riding centers.

Authors:  Katarzyna Wolny-Koładka; Anna Lenart-Boroń
Journal:  Environ Sci Pollut Res Int       Date:  2018-05-23       Impact factor: 4.223

6.  Whole genome sequencing of methicillin-resistant and methicillin-sensitive Staphylococcus aureus isolated from 4 horses in a veterinary teaching hospital and its ambulatory service.

Authors:  Paloma Morice; Marion Allano; Chantale Provost; Julie-Hélène Fairbrother; Carl A Gagnon; Frédéric Sauvé
Journal:  Can J Vet Res       Date:  2021-07       Impact factor: 1.310

7.  Low MRSA prevalence in horses at farm level.

Authors:  Annelies Van den Eede; Ann Martens; Isabelle Feryn; Wannes Vanderhaeghen; Urszula Lipinska; Frank Gasthuys; Patrick Butaye; Freddy Haesebrouck; Katleen Hermans
Journal:  BMC Vet Res       Date:  2012-11-07       Impact factor: 2.741

8.  Molecular epidemiology of environmental MRSA at an equine teaching hospital: introduction, circulation and maintenance.

Authors:  Joany van Balen; Jade Mowery; Micha Piraino-Sandoval; Rocio C Nava-Hoet; Catherine Kohn; Armando E Hoet
Journal:  Vet Res       Date:  2014-03-19       Impact factor: 3.683

9.  Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Acinetobacter baumannii among horses entering a veterinary teaching hospital: The contemporary "Trojan Horse".

Authors:  Birgit Walther; Katja-Sophia Klein; Ann-Kristin Barton; Torsten Semmler; Charlotte Huber; Silver Anthony Wolf; Karsten Tedin; Roswitha Merle; Franziska Mitrach; Sebastian Guenther; Antina Lübke-Becker; Heidrun Gehlen
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

10.  Prevalence, risk factors, and characterization of multidrug resistant and extended spectrum β-lactamase/AmpC β-lactamase producing Escherichia coli in healthy horses in France in 2015.

Authors:  Maud de Lagarde; Caroline Larrieu; Karine Praud; Catherine Schouler; Benoît Doublet; Guillaume Sallé; John M Fairbrother; Julie Arsenault
Journal:  J Vet Intern Med       Date:  2019-01-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.